153 related articles for article (PubMed ID: 15093587)
1. Comment on "Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results" by J.-M. Nabholtz et al.
Mouridsen HT; Chaudri-Ross HA
Eur J Cancer; 2004 May; 40(7):1095-6; author reply 1097. PubMed ID: 15093587
[No Abstract] [Full Text] [Related]
2. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial.
Thürlimann B; Hess D; Köberle D; Senn I; Ballabeni P; Pagani O; Perey L; Aebi S; Rochlitz C; Goldhirsch A
Breast Cancer Res Treat; 2004 Jun; 85(3):247-54. PubMed ID: 15111763
[TBL] [Abstract][Full Text] [Related]
3. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results.
Nabholtz JM; Bonneterre J; Buzdar A; Robertson JF; Thürlimann B
Eur J Cancer; 2003 Aug; 39(12):1684-9. PubMed ID: 12888362
[TBL] [Abstract][Full Text] [Related]
4. Focus on anastrozole and breast cancer.
Mokbel K
Curr Med Res Opin; 2003; 19(8):683-8. PubMed ID: 14687437
[TBL] [Abstract][Full Text] [Related]
5. Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women.
Vergote I; Bonneterre J; Thürlimann B; Robertson J; Krzakowski M; Mauriac L; Koralewski L; Webster A; Steinberg M; von Euler M
Eur J Cancer; 2000 Sep; 36 Suppl 4():S84-5. PubMed ID: 11056332
[TBL] [Abstract][Full Text] [Related]
6. Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Costa SD; Kaufmann M
J Clin Oncol; 2001 May; 19(9):2580; author reply 2580-2. PubMed ID: 11331346
[No Abstract] [Full Text] [Related]
7. Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Tonkin K
J Clin Oncol; 2001 May; 19(9):2579-80; author reply 2580-2. PubMed ID: 11331344
[No Abstract] [Full Text] [Related]
8. Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Copur MS; Ledakis P; Bolton M; Norvell M; Muhvic J
J Clin Oncol; 2001 May; 19(9):2578; author reply 2580-2. PubMed ID: 11331343
[No Abstract] [Full Text] [Related]
9. Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Bagley CM; Rowbotham RK
J Clin Oncol; 2001 May; 19(9):2578-9; author reply 2580-2. PubMed ID: 11331342
[No Abstract] [Full Text] [Related]
10. Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Panasci LC
J Clin Oncol; 2001 May; 19(9):2578; author reply 2580-2. PubMed ID: 11331341
[No Abstract] [Full Text] [Related]
11. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.
Nabholtz JM; Buzdar A; Pollak M; Harwin W; Burton G; Mangalik A; Steinberg M; Webster A; von Euler M
J Clin Oncol; 2000 Nov; 18(22):3758-67. PubMed ID: 11078488
[TBL] [Abstract][Full Text] [Related]
12. [Aromatase inhibitors: anastrozole versus tamoxifen as first-ine therapy for advanced postmenopausal breast cancer].
Bergmann L
Strahlenther Onkol; 2001 May; 177(5):273-4. PubMed ID: 11398617
[No Abstract] [Full Text] [Related]
13. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.
Bonneterre J; Thürlimann B; Robertson JF; Krzakowski M; Mauriac L; Koralewski P; Vergote I; Webster A; Steinberg M; von Euler M
J Clin Oncol; 2000 Nov; 18(22):3748-57. PubMed ID: 11078487
[TBL] [Abstract][Full Text] [Related]
14. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
Buzdar A; Jonat W; Howell A; Jones SE; Blomqvist C; Vogel CL; Eiermann W; Wolter JM; Azab M; Webster A; Plourde PV
J Clin Oncol; 1996 Jul; 14(7):2000-11. PubMed ID: 8683230
[TBL] [Abstract][Full Text] [Related]
15. Superior efficacy of letrozole versus tamoxifen as first-line therapy.
Buzdar AU
J Clin Oncol; 2002 Feb; 20(3):876-8. PubMed ID: 11821477
[No Abstract] [Full Text] [Related]
16. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
Smith IE; Dowsett M; Ebbs SR; Dixon JM; Skene A; Blohmer JU; Ashley SE; Francis S; Boeddinghaus I; Walsh G;
J Clin Oncol; 2005 Aug; 23(22):5108-16. PubMed ID: 15998903
[TBL] [Abstract][Full Text] [Related]
17. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study.
Milla-Santos A; Milla L; Portella J; Rallo L; Pons M; Rodes E; Casanovas J; Puig-Gali M
Am J Clin Oncol; 2003 Jun; 26(3):317-22. PubMed ID: 12796608
[TBL] [Abstract][Full Text] [Related]
18. Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen.
Buzdar AU
Expert Rev Anticancer Ther; 2002 Dec; 2(6):623-9. PubMed ID: 12503208
[TBL] [Abstract][Full Text] [Related]
19. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
Buzdar AU; Cuzick J
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1037s-1048s. PubMed ID: 16467122
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial.
Locker GY; Mansel R; Cella D; Dobrez D; Sorensen S; Gandhi SK;
Breast Cancer Res Treat; 2007 Dec; 106(2):229-38. PubMed ID: 17245540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]